Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Conditions
Brief summary
This clinical trial studies use of F-18 16 alpha-fluoroestradiol (\[F-18\] FES) positron emission tomography (PET)/computed tomography (CT) in measuring tumor hormone receptor expression in patients undergoing endocrine-targeted therapy for newly diagnosed breast cancer or breast cancer that has come back or spread to other places in the body. Comparing results of diagnostic procedures done before, during, and after hormone therapy may help measure a patient's response to treatment.
Detailed description
OUTLINE: Patients undergo F-18 FES PET/CT scan at baseline. Patients also undergo F-18 FES PET/CT and FDG PET/CT between 1-12 weeks after starting therapy, and then 1-12 weeks after the second FES PET/CT scan. Repeat FDG PET may be omitted in patients on selective estrogen receptor degrader. After completion of study, patients are followed up for up to 20 years.
Interventions
Undergo F-18 FES PET/CT
PROCEDUREPositron Emission Tomography
Undergo F-18 FES PET/CT
PROCEDUREComputed Tomography
Undergo F-18 FES PET/CT
DRUGFludeoxyglucose F-18
Undergo FDG PET/CT
OTHERLaboratory Biomarker Analysis
Correlative studies
Sponsors
University of Washington
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult, non-pregnant patients with biopsy-proven or clinically obvious primary, recurrent or metastatic breast cancer * Breast cancer from ER+ primary that is seen on other imaging tests. Tumor ER expression must have been confirmed by immunohistocytochemistry of primary tumor or recurrent disease. * At least one site of disease 1.5 cm or greater is needed to meet the spatial resolution limits of PET imaging. * Patients must have been off tamoxifen or other estrogen receptor blocking agents for at least 6 weeks and off chemotherapy for 3 weeks for the initial baseline FES. * Patients must be selected for an endocrine targeted therapy regimen for treatment of their breast cancer by the referring oncologist. Selected treatments may be part of experimental treatment protocols for which the patient would be separately consented. * Patients must be willing to undergo serial imaging procedures. * Patients must agree to allow access to clinical records regarding response to treatment and long term follow up. * Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
* An inability to lie still for the tests * Individuals weighing more than 300 lb. (this is the weight limit of the scanner table) * Pregnant or lactating. Women of childbearing potential with either a positive or no pregnancy test at baseline are excluded. * Any other life-threatening illness (e.g. serious, uncontrolled concurrent infection or clinically significant cardiac disease - congestive heart failure, symptomatic coronary artery disease, cardiac arrhythmia not well controlled with medication). * Use of tamoxifen, faslodex, DES or any other ER blocking agent \< 6 weeks or chemotherapy \< 3 weeks prior to imaging scan. * Uncontrolled diabetes mellitus (fasting glucose \> 200 mg/dL) * Adult patients who require monitored anesthesia for PET scanning.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in F-18 16 Alpha-fluoroestradiol (FES) Standardized Uptake Value (SUV) - Avg SULmax | From time of first F-18 FES-PET/CT scan to time of second F-18 FES-PET/CT scan (approximately 1-12 weeks) | FES uptake will be quantified using lean body mass adjusted SUV (SUL). Percentage change in FES average SULmax between baseline and a second FES scan will be calculated for up to 3 lesions per patient. |
| F-18 16 Alpha-fluoroestradiol (FES) Uptake | From time of first F-18 FES-PET/CT scan to time of second F-18 FES-PET/CT scan (approximately 1-12 weeks) | Quantitative measures of FES uptake for each disease site will be determined by drawing regions-of-interest on lesions to determine maximal FES uptake (SUVmax) per lesion. Up to 10 sites seen on the static torso survey will be quantified. |
| Proportion of Patients With a Threshold of Percentage Change, or That Surpass a Targeted Follow-up F-18 16 Alpha-fluoroestradiol (FES) Standardized Uptake Value (SUV) | From time of first F-18 FES-PET/CT scan to time of second F-18 FES-PET/CT scan (approximately 1-12 weeks) | The number of patients showing a 20% increase in FES uptake (SULmean or SUVmax) compared to baseline from the first to second scan using a 90% Wilson score binomial confidence interval. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to Disease Progression | From start of therapy up to 20 years | Time to disease progression will be measured as the time from the start of endocrine therapy to the time the patient is first recorded as having disease progression. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORHannah Linden
Fred Hutch/University of Washington Cancer Consortium
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Diagnostic (F-18 FES PET/CT) Patients undergo F-18 FES PET/CT scan at baseline. Patients also undergo F-18 FES PET/CT and FDG PET/CT between 1-12 weeks after starting therapy. Repeat FDG PET may be omitted in patients on selective estrogen receptor degrader. | 2 |
| Total | 2 |
Baseline characteristics
| Characteristic | Diagnostic (F-18 FES PET/CT) |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 2 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants |
| Age, Continuous | 71 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 2 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 2 Participants |
| Region of Enrollment United States | 2 participants |
| Sex: Female, Male Female | 2 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 2 |
| other Total, other adverse events | 0 / 2 |
| serious Total, serious adverse events | 0 / 2 |
Outcome results
Primary
Change in F-18 16 Alpha-fluoroestradiol (FES) Standardized Uptake Value (SUV) - Avg SULmax
FES uptake will be quantified using lean body mass adjusted SUV (SUL). Percentage change in FES average SULmax between baseline and a second FES scan will be calculated for up to 3 lesions per patient.
Time frame: From time of first F-18 FES-PET/CT scan to time of second F-18 FES-PET/CT scan (approximately 1-12 weeks)
Population: 2 patients had 2 FES scans each
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Diagnostic (F-18 FES PET/CT) | Change in F-18 16 Alpha-fluoroestradiol (FES) Standardized Uptake Value (SUV) - Avg SULmax | 78 Percentage decrease in avgSUL |
Primary
F-18 16 Alpha-fluoroestradiol (FES) Uptake
Quantitative measures of FES uptake for each disease site will be determined by drawing regions-of-interest on lesions to determine maximal FES uptake (SUVmax) per lesion. Up to 10 sites seen on the static torso survey will be quantified.
Time frame: From time of first F-18 FES-PET/CT scan to time of second F-18 FES-PET/CT scan (approximately 1-12 weeks)
Population: 2 patients had 2 scans each
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Diagnostic (F-18 FES PET/CT) | F-18 16 Alpha-fluoroestradiol (FES) Uptake | FES scan 1 | 5.7 average SUVmax |
| Diagnostic (F-18 FES PET/CT) | F-18 16 Alpha-fluoroestradiol (FES) Uptake | FES scan 2 | 1.4 average SUVmax |
Primary
Proportion of Patients With a Threshold of Percentage Change, or That Surpass a Targeted Follow-up F-18 16 Alpha-fluoroestradiol (FES) Standardized Uptake Value (SUV)
The number of patients showing a 20% increase in FES uptake (SULmean or SUVmax) compared to baseline from the first to second scan using a 90% Wilson score binomial confidence interval.
Time frame: From time of first F-18 FES-PET/CT scan to time of second F-18 FES-PET/CT scan (approximately 1-12 weeks)
Population: 2 patients had 2 FES scans each
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Diagnostic (F-18 FES PET/CT) | Proportion of Patients With a Threshold of Percentage Change, or That Surpass a Targeted Follow-up F-18 16 Alpha-fluoroestradiol (FES) Standardized Uptake Value (SUV) | 0 participants with increased FES uptake |
Secondary
Time to Disease Progression
Time to disease progression will be measured as the time from the start of endocrine therapy to the time the patient is first recorded as having disease progression.
Time frame: From start of therapy up to 20 years